Stryker's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Stryker's ROA in the second quarter of 2026?
Stryker Corp achieved a return on average assets (ROA) of 7.85 % in its second quarter of 2026, which is below Stryker's average return on assets, which stands at 9.51%.

ROA has improved compared to 7.11% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 119 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 881, from total ROA ranking in the first quarter of 2026 at 1048.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	5.48 %	1.14 %	11.08 %	7.75 %	19.4 %
Y / Y Net Income Change	44.34 %	13.91 %	55.49 %	3 %	7.15 %
Net Income (TTM) in million	3,729	3,337	3,246	2,943	2,918
Return On Assets (TTM)	7.85 %	7.11 %	6.94 %	6.46 %	6.53 %
SYK's Total Ranking	# 881	# 1048	# 953	# 953	# 940
Total Assets (TTM) in million	47,961	45,711	50,187	46,267	45,468
Seq. Total Assets Change	4.92 %	-8.92 %	8.47 %	1.76 %	0.6 %
Seq. Net Income Change	71.28 %	-12.25 %	-1.16 %	-2.83 %	35.17 %

SYK's 5 Years Annual ROA >> Back to SYK Management Effectiveness >> Compare SYK ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 35
Sector	# 120
Overall	# 776

Return On Assets Statistics
High	Average	Low
15.63 %	9.51 %	3 %
(June 30. 2007)		IV. Quarter

Financial Statements
Stryker's Assets	$ 47,961 million	SYK's Balance sheet
Stryker's Income	$ 1,276 million	Quarterly SYK's Income Statement
SYK's Income by Division		See SYK's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	11.08 %	7.84 %	13.59 %	6.51 %	0.88 %
Total Assets in million	50,187	45,181	41,895	36,884	34,631
Y / Y Net Income Change	8.45 %	-5.43 %	34.22 %	18.25 %	24.7 %
Net Income in million	3,246	2,993	3,165	2,358	1,994
Annual Return On Assets	6.47 %	6.62 %	7.55 %	6.39 %	5.76 %

SYK's 5 Years Annual ROA >> Back to SYK Management Effectiveness >> Compare SYK ROA to its Competitors

Comment on SYK's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA deteriorated to 6.47 %, despite annual net income growth of 8.45 % to $3,246.00 million, from $2,993.00 million a year ago, as SYK's assets increase to $50,187.00 million, by 8.45 %.

More Return On Assets Ratios
SYK's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SYK's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SYK's Competitors
Subscribers only: Roa for Stryker's Suppliers
Subscribers only: Return On Assets for SYK's Customers

You may also want to know
SYK's Roi	SYK's Inventory Turnover Ratio	SYK's Growth Rates	SYK's Dividend Comparisons
	SYK's Profitability Ratios	SYK's Asset Turnover Ratio	SYK's Dividend Growth
SYK's Roe	SYK's Valuation Ratios	SYK's Financial Strength Ratios	SYK's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %
Iradimed Corporation	20.36 %
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %
Arcutis Biotherapeutics Inc	14.23 %
Harmony Biosciences Holdings inc	14.15 %
Biolife Solutions Inc	14.09 %
Aveanna Healthcare Holdings Inc	13.82 %
West Pharmaceutical Services Inc	13.64 %
Medinotec Inc	13.38 %
Puma Biotechnology Inc	13.28 %
Sbc Medical Group Holdings Incorporated	13.26 %
Alpha Pro Tech Ltd	13.17 %

Date modified: 2026-09-26T07:00:27+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.